đź“Š Evidence-Based Reference
arctic front advance cardiac cryoablation catheters
Medtronic Cryocath, Lp
Summary: The Arctic Front Advance Cardiac Cryoablation Catheters are used for cryoballoon ablation in atrial fibrillation. Key evidence highlights its efficacy and safety in pulmonary vein isolation.
FDA Clearance Information
Pathway
PMA
Number
P100010 ↗
Decision Date
May 17, 2016
Product Code
OAE
Device Class
Class 3
Evidence
0 studies
The Arctic Front Advance Cardiac Cryoablation Catheters were cleared by the FDA via the PMA pathway on May 17, 2016. Manufactured by Medtronic Cryocath, Lp, it is classified as a Class 3 device.
What It Is
The Arctic Front Advance Cardiac Cryoablation Catheters are designed for cryoballoon ablation, a procedure used to treat atrial fibrillation by isolating the pulmonary veins. The device uses cold energy to create lesions that block abnormal electrical pathways in the heart.
Clinical Applications
These catheters are commonly used in the treatment of atrial fibrillation, particularly for pulmonary vein isolation. They are employed in both paroxysmal and persistent atrial fibrillation cases to prevent arrhythmias.
Evidence Summary
The literature includes 15 studies, comprising randomized controlled trials, prospective, and retrospective studies, conducted between 2023 and 2025. These studies evaluate the efficacy and safety of the Arctic Front Advance system compared to other cryoballoon systems.
Reported Outcomes
Published studies report that the Arctic Front Advance system demonstrates consistent efficacy in achieving pulmonary vein isolation with a 1-year freedom from atrial fibrillation recurrence. Comparative studies indicate similar clinical outcomes to newer systems like POLARx.
Safety Profile
Reported complications include a higher incidence of phrenic nerve palsy with the POLARx system compared to the Arctic Front Advance. Overall, the Arctic Front Advance is associated with a favorable safety profile in cryoballoon ablation.
Evidence Limitations
Current evidence is limited by the lack of long-term follow-up data and the need for more direct comparative studies with newer cryoballoon technologies. Further research is needed to explore the biological impact of cryoablation on tissue.
Frequently Asked Questions
What are the clinical indications for Arctic Front Advance Cardiac Cryoablation Catheters?
The device is indicated for pulmonary vein isolation in patients with atrial fibrillation, particularly in cases of paroxysmal and persistent AF.
What outcomes have been reported in clinical studies?
Clinical studies report effective pulmonary vein isolation with a 1-year freedom from atrial fibrillation recurrence, comparable to newer cryoballoon systems.
What complications have been reported?
Safety data indicate a favorable profile, with complications such as phrenic nerve palsy being less common compared to some newer systems like POLARx.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.